clinical trial · NCT05811754
Safety of Herpes Zoster Subunit (HZ/su) Vaccine During Pregnancy in Adult Women With Immunocompromised Conditions
GlaxoSmithKline·—·active not recruiting·n = 2,844
Herpes ZosterData collection
brief summary
The purpose of this post-marketing commitment safety study is to evaluate the real-world safety of HZ/su vaccine during pregnancy in immunodeficient or immunosuppressed adult pregnant women between 18 and 49 years of age in the United States. The primary outcome of interest is major congenital malformations (MCMs).
started
May 9, 2022
primary completion
Mar 31, 2028
completion
Mar 31, 2028
last updated
Nov 12, 2025
official title
Post-marketing Commitment Safety Study of HZ/su to Evaluate Pregnancy Exposures and Outcomes in Immunodeficient or Immunosuppressed Women Between 18 and 49 Years of Age
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol